A single center, open-label trial in subjects with severe renal impairment evaluating the dialysability of the sugammadex-rocuronium complex
Latest Information Update: 09 May 2022
At a glance
- Drugs Sugammadex (Primary) ; Rocuronium bromide
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 25 Sep 2014 New trial record